The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).

PubWeight™: 3.50‹?› | Rank: Top 1%

🔗 View Article (PMC 4156910)

Published in Clin Trials on June 05, 2014

Authors

Walter T Ambrosius1, Kaycee M Sink2, Capri G Foy3, Dan R Berlowitz4, Alfred K Cheung5, William C Cushman6, Lawrence J Fine7, David C Goff8, Karen C Johnson9, Anthony A Killeen10, Cora E Lewis11, Suzanne Oparil12, David M Reboussin13, Michael V Rocco14, Joni K Snyder7, Jeff D Williamson2, Jackson T Wright15, Paul K Whelton16, SPRINT Study Research Group

Author Affiliations

1: Department of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA wambrosi@wakehealth.edu.
2: Section on Gerontology and Geriatric Medicine, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.
3: Department of Social Sciences & Health Policy, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA.
4: Center for Healthcare Organization and Implementation Research, Bedford Veterans Affairs Hospital, Bedford, MA, USA.
5: Department of Internal Medicine, University of Utah and Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, UT, USA.
6: Preventive Medicine Section, Veterans Affairs Medical Center, Memphis, TN, USA.
7: Clinical Applications and Prevention Branch, Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD, USA.
8: Department of Epidemiology, Colorado School of Public Health, Aurora, CO, USA.
9: Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
10: Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.
11: Division of Preventive Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
12: Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
13: Department of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA.
14: Section on Nephrology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.
15: Division of Nephrology and Hypertension, Department of Medicine, Case Western Reserve University, Cleveland, OH, USA.
16: Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA.

Associated clinical trials:

Systolic Blood Pressure Intervention Trial (SPRINT) | NCT01206062

Articles citing this

A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14

Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial. JAMA (2016) 5.67

Generalizability of SPRINT Results to the U.S. Adult Population. J Am Coll Cardiol (2015) 2.14

Baseline characteristics of African Americans in the Systolic Blood Pressure Intervention Trial. J Am Soc Hypertens (2015) 2.11

Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial. Kidney Int (2014) 1.71

Primary prevention: do the very elderly require a different approach? Trends Cardiovasc Med (2014) 1.43

Characterizing Frailty Status in the Systolic Blood Pressure Intervention Trial. J Gerontol A Biol Sci Med Sci (2016) 0.97

SPRINT Trial Results: Latest News in Hypertension Management. Hypertension (2015) 0.88

Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association. Hypertension (2016) 0.87

Hypertension and Its Role in Cognitive Function: Current Evidence and Challenges for the Future. Am J Hypertens (2015) 0.86

Blood Pressure in Older Adults: the Importance of Frailty. Curr Hypertens Rep (2015) 0.85

The SPRINT study: Outcome may be driven by difference in diuretic treatment demasking heart failure and study design may support systolic blood pressure target below 140 mmHg rather than below 120 mmHg. Blood Press (2016) 0.84

Effect of Intensive Versus Standard Clinic-Based Hypertension Management on Ambulatory Blood Pressure: Results From the SPRINT (Systolic Blood Pressure Intervention Trial) Ambulatory Blood Pressure Study. Hypertension (2016) 0.84

Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey). Circulation (2017) 0.84

Clinician's guide to the updated ABCs of cardiovascular disease prevention. J Am Heart Assoc (2014) 0.82

Hypertension-attributed nephropathy: what's in a name? Nat Rev Nephrol (2015) 0.82

US Hypertension Management Guidelines: A Review of the Recent Past and Recommendations for the Future. J Am Heart Assoc (2015) 0.82

APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume. Kidney Int (2016) 0.81

A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline. Alzheimers Res Ther (2016) 0.81

Managing Hypertension in Patients with CKD: A Marathon, Not a SPRINT. J Am Soc Nephrol (2015) 0.79

Assessing Sex Differences in the Risk of Cardiovascular Disease and Mortality per Increment in Systolic Blood Pressure: A Systematic Review and Meta-Analysis of Follow-Up Studies in the United States. PLoS One (2017) 0.79

Chronic kidney disease, cerebral blood flow, and white matter volume in hypertensive adults. Neurology (2016) 0.78

SPS3 Evidence Supports Intensive Blood Pressure Control. Circulation (2016) 0.78

Effects of Intensive BP Control in CKD. J Am Soc Nephrol (2017) 0.78

Underrepresentation of African-Americans in Alzheimer's Trials: A Call for Affirmative Action. Front Aging Neurosci (2016) 0.77

Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology Collaboration Definitions. Am J Nephrol (2016) 0.77

Current and Future Treatment of Hypertension in the SPRINT Era. Methodist Debakey Cardiovasc J (2016) 0.77

Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients with Hypertension: The Systolic Blood Pressure Intervention (SPRINT) Trial. Circulation (2017) 0.77

Does Age Matter? Association Between Usual Source of Care and Hypertension Control in the US Population: Data From NHANES 2007-2012. Am J Hypertens (2016) 0.76

Center for stroke disparities solutions community- based care transition interventions: study protocol of a randomized controlled trial. Trials (2015) 0.75

Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial. Circ Heart Fail (2017) 0.75

Hypertension in 2016: Blood pressure goals, variability and SGLT2 blockade in CKD. Nat Rev Nephrol (2016) 0.75

Baseline blood pressure control in Hispanics: characteristics of Hispanics in the Systolic Blood Pressure Intervention Trial. J Clin Hypertens (Greenwich) (2016) 0.75

The association between Self-Reported Medication Adherence scores and systolic blood pressure control: a SPRINT baseline data study. J Am Soc Hypertens (2016) 0.75

BP Targets in Older Adults with CKD: Additional Evidence, but Uncertainty Continues. Clin J Am Soc Nephrol (2015) 0.75

Patterns and Correlates of Baseline Thiazide-Type Diuretic Prescription in the Systolic Blood Pressure Intervention Trial. Hypertension (2016) 0.75

Achievement of individualized treatment targets in patients with comorbid type-2 diabetes and hypertension: 6 months results of the DIALOGUE registry. BMC Endocr Disord (2015) 0.75

Recruitment strategies and challenges in a large intervention trial: Systolic Blood Pressure Intervention Trial. Clin Trials (2016) 0.75

Blood Pressure, Sexual Activity, and Dysfunction in Women With Hypertension: Baseline Findings From the Systolic Blood Pressure Intervention Trial (SPRINT). J Sex Med (2016) 0.75

SPRINT and Implications for Target Organ Protection in African Americans. Ethn Dis (2016) 0.75

Hypertension treatment and falls: should we be concerned? J Gen Intern Med (2014) 0.75

Antihypertensive medications and sexual function in women: baseline data from the SBP intervention trial (SPRINT). J Hypertens (2016) 0.75

Orthostatic changes in systolic blood pressure among SPRINT participants at baseline. J Am Soc Hypertens (2016) 0.75

Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. Diabetes Care (2017) 0.75

APOL1 Gene Kidney Risk Variants and Cardiovascular Disease: Getting to the Heart of the Matter. Am J Kidney Dis (2017) 0.75

Cognitive Function and Kidney Disease: Baseline Data From the Systolic Blood Pressure Intervention Trial (SPRINT). Am J Kidney Dis (2017) 0.75

The 2017 Focused Update of the Guidelines of the Taiwan Society of Cardiology (TSOC) and the Taiwan Hypertension Society (THS) for the Management of Hypertension. Acta Cardiol Sin (2017) 0.75

APOL1 renal-risk variants do not associate with incident cardiovascular disease or mortality in the Systolic Blood Pressure Intervention Trial. KI Rep (2017) 0.75

Changing concepts in hypertension management. J Hum Hypertens (2017) 0.75

Articles cited by this

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28

The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med (2001) 76.04

A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 50.94

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet (2002) 40.37

Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA (1999) 40.00

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA (2002) 36.26

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA (2014) 34.12

Global burden of hypertension: analysis of worldwide data. Lancet (2005) 32.76

The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc (2005) 27.90

General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation (2008) 26.42

Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet (1990) 25.12

Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet (1990) 24.72

Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49

Treatment of hypertension in patients 80 years of age or older. N Engl J Med (2008) 21.04

EQ-5D: a measure of health status from the EuroQol Group. Ann Med (2001) 18.69

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA (1991) 14.36

The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther (2000) 13.16

The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med (1994) 11.65

Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med (2001) 10.54

Measurement of functional activities in older adults in the community. J Gerontol (1982) 10.07

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet (2000) 9.78

Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) Lancet (1991) 9.57

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet (1997) 9.18

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet (2005) 9.00

The progression from hypertension to congestive heart failure. JAMA (1996) 7.56

Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res (1999) 7.14

Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke (2009) 6.62

Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation (2003) 6.47

Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet (1998) 6.20

Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA (1997) 5.91

The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther (2005) 5.42

Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet (2013) 5.20

Race-ethnic disparities in the impact of stroke risk factors: the northern Manhattan stroke study. Stroke (2001) 4.07

Development and initial validation of the Falls Efficacy Scale-International (FES-I). Age Ageing (2005) 4.01

Hypertension and the risk of mild cognitive impairment. Arch Neurol (2007) 3.62

Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol (2008) 3.28

Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension (2001) 3.16

Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension (2006) 3.02

Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med (2003) 3.02

Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med (2005) 2.90

A validation study of the Dementia Questionnaire. Arch Neurol (1994) 2.89

Classification of heart failure in the atherosclerosis risk in communities (ARIC) study: a comparison of diagnostic criteria. Circ Heart Fail (2012) 2.88

A computerized algorithm for etiologic classification of ischemic stroke: the Causative Classification of Stroke System. Stroke (2007) 2.63

Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999-2000. Arch Intern Med (2004) 2.52

The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med (1999) 2.40

Guidelines on preventing cardiovascular disease in clinical practice. BMJ (2000) 2.15

Cardiovascular risk factors and Alzheimer's disease. Curr Atheroscler Rep (2004) 2.00

Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. 1979. JAMA (1997) 1.67

Interphysician agreement in the diagnosis of subtypes of acute ischemic stroke: implications for clinical trials. The TOAST Investigators. Neurology (1993) 1.63

Updated U.S. population standard for the Veterans RAND 12-item Health Survey (VR-12). Qual Life Res (2008) 1.60

Update on hypertension and Alzheimer's disease. Neurol Res (2006) 1.55

Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). Am J Hypertens (2005) 1.47

Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med (2002) 1.43

Low mortality from all causes, including myocardial infarction, in well-controlled hypertensives treated with a beta-blocker plus other antihypertensives. J Hypertens (1987) 1.31

Validation of a cognitive assessment battery administered over the telephone. J Am Geriatr Soc (2012) 1.26

Hypertension, hypertension-clustering factors and Alzheimer's disease. Neurol Res (2003) 1.14

The science of web-based clinical trial management. Clin Trials (2005) 0.89

Antihypertensive treatment and the J-curve. Cardiovasc Drugs Ther (2000) 0.84

Cost effectiveness of intensive treatment of hypertension. Based on presentations by Donald S. Shepard, PhD; and Dominic Hodgkin, PhD. Am J Manag Care (1998) 0.79

A new twist in the J-shape curve? J Am Geriatr Soc (1999) 0.79

Cardiovascular disease in the United States: an epidemiologic overview. Cardiovasc Clin (1991) 0.79

Articles by these authors

Baseline characteristics of African Americans in the Systolic Blood Pressure Intervention Trial. J Am Soc Hypertens (2015) 2.11

Characterizing Frailty Status in the Systolic Blood Pressure Intervention Trial. J Gerontol A Biol Sci Med Sci (2016) 0.97

SPRINT Trial Results: Latest News in Hypertension Management. Hypertension (2015) 0.88

Sleep duration, cognitive decline, and dementia risk in older women. Alzheimers Dement (2015) 0.85

Effect of Intensive Versus Standard Clinic-Based Hypertension Management on Ambulatory Blood Pressure: Results From the SPRINT (Systolic Blood Pressure Intervention Trial) Ambulatory Blood Pressure Study. Hypertension (2016) 0.84

Urinary Tract Stones and Osteoporosis: Findings From the Women's Health Initiative. J Bone Miner Res (2015) 0.81

Chronic kidney disease, cerebral blood flow, and white matter volume in hypertensive adults. Neurology (2016) 0.78

Electrocardiographic measures of left ventricular hypertrophy in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Am Soc Hypertens (2016) 0.77

Measuring vascular reactivity with resting-state blood oxygenation level-dependent (BOLD) signal fluctuations: A potential alternative to the breath-holding challenge? J Cereb Blood Flow Metab (2016) 0.76

Blood Pressure, Sexual Activity, and Dysfunction in Women With Hypertension: Baseline Findings From the Systolic Blood Pressure Intervention Trial (SPRINT). J Sex Med (2016) 0.75

Patterns and Correlates of Baseline Thiazide-Type Diuretic Prescription in the Systolic Blood Pressure Intervention Trial. Hypertension (2016) 0.75

The association between Self-Reported Medication Adherence scores and systolic blood pressure control: a SPRINT baseline data study. J Am Soc Hypertens (2016) 0.75

Dietary Inflammatory Index, Bone Mineral Density and Risk of Fracture in Postmenopausal Women: Results from the Women's Health Initiative. J Bone Miner Res (2016) 0.75

Orthostatic changes in systolic blood pressure among SPRINT participants at baseline. J Am Soc Hypertens (2016) 0.75

Variability and rapid increase in body mass index during childhood are associated with adult obesity. Int J Epidemiol (2015) 0.75

Recruitment strategies and challenges in a large intervention trial: Systolic Blood Pressure Intervention Trial. Clin Trials (2016) 0.75

Cognitive Function and Kidney Disease: Baseline Data From the Systolic Blood Pressure Intervention Trial (SPRINT). Am J Kidney Dis (2017) 0.75

Serum 25-hydroxyvitamin D concentrations and lung cancer risk in never-smoking postmenopausal women. Cancer Causes Control (2017) 0.75

The association between insulin resistance and atrial fibrillation: A cross-sectional analysis from SPRINT (Systolic Blood Pressure Intervention Trial). J Clin Hypertens (Greenwich) (2017) 0.75

Comparison of an alternative schedule of extended care contacts to a self-directed control: a randomized trial of weight loss maintenance. Int J Behav Nutr Phys Act (2017) 0.75

Association of Albuminuria and Estimated Glomerular Filtration Rate with Functional Performance Measures in Older Adults with Chronic Kidney Disease. Am J Nephrol (2017) 0.75

Long-term impact of intensive lifestyle intervention on cognitive function assessed with the National Institutes of Health Toolbox: The Look AHEAD study. Alzheimers Dement (Amst) (2017) 0.75

Association of Tea-drinking Habits with the Risk of Non-Hodgkin Lymphoma - A Prospective Cohort Study among Postmenopausal Women. Br J Nutr (2022) 0.75